Profile image
Story Views

Last Hour:
Last 24 Hours:

Human Albumin Market 2016 Size, Trends, Growth, Analysis and Forecasts

Tuesday, March 7, 2017 2:46
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Albumin-based therapies such as Idelvion (CSL654 rIX-FP) by CSL Behring received marketing approval from the US FDA in March 2016 and from the EMA in May 2016. Apart from these, Albutropin (TV-1106) by Teva Pharmaceuticals, Ampion by Ampio Pharmaceuticals, and Albutein by Grifols (for Alzheimer’s disease) are expected to enter the market during the forecast period. 
The demand for albumin is high in APAC in countries like India and China. Still, the uptake of these therapeutics is less due to the lack of awareness about these products and their therapeutic uses. Thus, the awareness programs conducted by organizations such as PPTA, which includes International Plasma Awareness Week, to help increase the awareness about plasma donation and the different plasma protein therapies available, along with their potential uses, is expected to increase the uptake of these therapeutics in treating various conditions.

Publisher’s analysts forecast the global human albumin market to grow at a CAGR of 4.97% during the period 2016-2020.

For more information about this report:          

Covered in this report 
The report covers the present scenario and the growth prospects of the global human albumin market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic albumin drugs used to treat infections, liver diseases, shock, during surgery, and severe burns. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched in the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography: 
- Americas

Publisher’s report, Global Human Albumin Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. 

Key vendors 
- CSL Behring 
- Grifols 
- Baxalta 
- Octapharma
- Kedrion


Request Sample Copy at                 


Other prominent vendors 
- AADi
- Ablynx 
- Albumedix 
- Ampio Pharmaceuticals 
- Azaya Therapeutics
- Beijing Tiantan 
- Biotest
- Bristol-Myers Squibb
- Celgene
- ConjuChem
- Hebei Changshan Biochem Pharma 
- HiMedia Laboratories
- Hualan Biological Engineering 
- InVittria
- MedxBio
- Merck
- Mitsubishi Tanabe Pharma
- NantBioScience
- Novo Nordisk
- Novozymes
- Shanghai RAAS Blood Products 
- Sucampo Pharmaceuticals 
- Teva Pharmaceuticals 
- Thermo Fisher Scientific
- Tianjin SinoBiotech & Beijing Bio-Fortune 
- Ventria Bioscience
- Yoshitomi Pharmaceutical

Market driver 
- High demand for human albumin in China
- For a full, detailed list, view our report 

Market challenge 
- Spread of pathogenic contaminants
- For a full, detailed list, view our report 

Market trend 
- Rise in non-therapeutic applications
- For a full, detailed list, view our report 

Inquire for Report at             

Contact Us:

Call: +1-646-491-9876

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.